AI is compressing drug discovery timelines. Cell therapies are moving from boutique treatments to scalable manufacturing. Longevity research is producing its first clinical-stage interventions. The founders building these companies and the pharma leaders evaluating them are both at SynBioBeta this May. So are the investors funding them and the government agencies backing the foundational research.
What you'll find in this part of the program: Xaira, GSK, Noetik, and Recursion on virtual biology and bridging the gap between cell-level predictions and real patient outcomes Jacob Glanville and Tim Friede on programmable immunity and the path from 200+ snake bites to engineered universal antivenom J&J and Eli Lilly on how startups become pharma-ready and how external innovation teams evaluate partnerships Latent Labs, Strand, and Sanofi on AI-designed RNA medicines and molecular therapeutics Boltz, Novo Nordisk, and UCSF on modeling protein dynamics in motion David Sinclair, Leroy Hood, Jeanne Loring, and ARPA-H on longevity, tissue replacement, and the biology of aging.
The Startups Founders to Meet, Fund and Partner with.
Backers of The Human Health Ecosystem
Also in the building:
Also in the building:
Who’s Coming to SynBioBeta?
“SynBioBeta is a who’s who of AI and biology.
This is where the future is being built, so don't miss it”
Eric Schmidt
Former CEO
"For every single fund at Boom Capital, one of our best companies has come directly from SynBioBeta. I met Mammoth Bio at SynBioBeta, and I met Nabla Bio at SynBioBeta."
Celestine Schnugg
Founder
"Nabla was accelerated into existence because of SynBioBeta. I met Seth Bannon from 50 Years, Cee Cee Schnugg from Boom Capital, and others from Y Combinator there, and those same people seeded Nabla. The vibe, leverage, and energy at SynBioBeta are unreal."
Surge Biswas
Founder
"Our Series A came together because of a little bit of SynBioBeta magic. I’ve been attending for a decade and it’s been inspiring to watch the field evolve from a lot of hopes and dreams to real products and applications."
Jacob Glanville
Founder & CEO
"I met Algen at SynBioBeta and later invested in the company. It’s exactly the kind of connection that makes the community so valuable."
Bill Tai
Co-founder
An extraordinary and extraordinarily important conference, the only conference where I feel I learn a lot. SynBioBeta is my tribe!
Martine Rothblatt
Founder & CEO
"I first met Centivax at SynBioBeta - and then led their Series A."
Steve Jurvetson
Co-Founder
The 1:1 Partnering App lets you see who's attending and set up meetings before you arrive.
If you're building therapeutics, evaluating what AI-native startups can do for your pipeline, investing in health, or tracking how fast this field is moving, this is a concentrated few days for it.
